JAK2V617F allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy

Richard T. Silver; Katherine Vandris; Y. Lynn Wang; Fernando Adriano; Amy V. Jones; Paul J. Christos; Nicholas C.P. Cross

doi:10.1016/j.leukres.2010.06.017

JAK2^V617F allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy

Richard T. Silver
, Katherine Vandris
, Y. Lynn Wang
, Fernando Adriano
, Amy V. Jones
, Paul J. Christos
, Nicholas C.P. Cross

Cornell University
University of Southampton
New York Presbyterian Hospital
Salisbury NHS Foundation Trust
Wessex Regional Genetics Laboratory

Research output: Contribution to journal › Article › peer-review

55 Scopus citations

Abstract

In a series of 105 patients with polycythemia vera, we retrospectively determined whether the JAK2^V617F mutation correlated with severity of disease phenotype. Higher JAK2^V617F allele burden correlated with more advanced myelofibrosis, greater splenomegaly, and higher white blood cell count, but not with age, gender, hematocrit level, or frequency of phlebotomy prior to cytoreductive therapy. Although a subgroup at increased risk for thrombosis was not clearly defined, there was a suggestion that frequency of thrombosis increased as the JAK2^V617F allele burden increased. The JAK2^V617F allele burden did not change significantly in treated patients with serial JAK2 analyses.

Original language	English
Pages (from-to)	177-182
Number of pages	6
Journal	Leukemia Research
Volume	35
Issue number	2
DOIs	https://doi.org/10.1016/j.leukres.2010.06.017
State	Published - Feb 2011

Keywords

Adult
Aged
Alleles
DNA Mutational Analysis
Female
Humans
Immunosuppressive Agents/therapeutic use
Janus Kinase 2/genetics
Male
Middle Aged
Polycythemia Vera/complications
Primary Myelofibrosis/drug therapy
Retrospective Studies

Access to Document

10.1016/j.leukres.2010.06.017

Cite this

@article{f0eeb16017174a64ba78391bc7b73243,

title = "JAK2V617F allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy",

abstract = "In a series of 105 patients with polycythemia vera, we retrospectively determined whether the JAK2V617F mutation correlated with severity of disease phenotype. Higher JAK2V617F allele burden correlated with more advanced myelofibrosis, greater splenomegaly, and higher white blood cell count, but not with age, gender, hematocrit level, or frequency of phlebotomy prior to cytoreductive therapy. Although a subgroup at increased risk for thrombosis was not clearly defined, there was a suggestion that frequency of thrombosis increased as the JAK2V617F allele burden increased. The JAK2V617F allele burden did not change significantly in treated patients with serial JAK2 analyses.",

keywords = "Adult, Aged, Alleles, DNA Mutational Analysis, Female, Humans, Immunosuppressive Agents/therapeutic use, Janus Kinase 2/genetics, Male, Middle Aged, Polycythemia Vera/complications, Primary Myelofibrosis/drug therapy, Retrospective Studies",

author = "Silver, \{Richard T.\} and Katherine Vandris and Wang, \{Y. Lynn\} and Fernando Adriano and Jones, \{Amy V.\} and Christos, \{Paul J.\} and Cross, \{Nicholas C.P.\}",

year = "2011",

month = feb,

doi = "10.1016/j.leukres.2010.06.017",

language = "English",

volume = "35",

pages = "177--182",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd.",

number = "2",

}

TY - JOUR

T1 - JAK2V617F allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy

AU - Silver, Richard T.

AU - Vandris, Katherine

AU - Wang, Y. Lynn

AU - Adriano, Fernando

AU - Jones, Amy V.

AU - Christos, Paul J.

AU - Cross, Nicholas C.P.

PY - 2011/2

Y1 - 2011/2

N2 - In a series of 105 patients with polycythemia vera, we retrospectively determined whether the JAK2V617F mutation correlated with severity of disease phenotype. Higher JAK2V617F allele burden correlated with more advanced myelofibrosis, greater splenomegaly, and higher white blood cell count, but not with age, gender, hematocrit level, or frequency of phlebotomy prior to cytoreductive therapy. Although a subgroup at increased risk for thrombosis was not clearly defined, there was a suggestion that frequency of thrombosis increased as the JAK2V617F allele burden increased. The JAK2V617F allele burden did not change significantly in treated patients with serial JAK2 analyses.

AB - In a series of 105 patients with polycythemia vera, we retrospectively determined whether the JAK2V617F mutation correlated with severity of disease phenotype. Higher JAK2V617F allele burden correlated with more advanced myelofibrosis, greater splenomegaly, and higher white blood cell count, but not with age, gender, hematocrit level, or frequency of phlebotomy prior to cytoreductive therapy. Although a subgroup at increased risk for thrombosis was not clearly defined, there was a suggestion that frequency of thrombosis increased as the JAK2V617F allele burden increased. The JAK2V617F allele burden did not change significantly in treated patients with serial JAK2 analyses.

KW - Adult

KW - Aged

KW - Alleles

KW - DNA Mutational Analysis

KW - Female

KW - Humans

KW - Immunosuppressive Agents/therapeutic use

KW - Janus Kinase 2/genetics

KW - Male

KW - Middle Aged

KW - Polycythemia Vera/complications

KW - Primary Myelofibrosis/drug therapy

KW - Retrospective Studies

UR - https://www.scopus.com/pages/publications/78751706637

U2 - 10.1016/j.leukres.2010.06.017

DO - 10.1016/j.leukres.2010.06.017

M3 - Article

C2 - 20650526

SN - 0145-2126

VL - 35

SP - 177

EP - 182

JO - Leukemia Research

JF - Leukemia Research

IS - 2

ER -

JAK2^V617F allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this